Starpharma Holdings Limited (SPL.AX)
| Previous close | 1.5000 |
| Open | 1.5050 |
| Bid | 1.5700 x 334700 |
| Ask | 1.6000 x 1317400 |
| Day's range | 1.5000 - 1.6100 |
| 52-week range | 1.0150 - 2.5200 |
| Volume | 686,649 |
| Avg. volume | 628,665 |
| Market cap | 641.603M |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0510 |
| Earnings date | 24 Aug 2021 - 30 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 25 Mar 1988 |
| 1y target est | 1.44 |
- GlobeNewswire
Starpharma to Webcast Live at Life Sciences Investor Forum June 24th
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comMELBOURNE, Australia, June 24, 2021 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, OTCQX: SPHRY), based in Melbourne, Australia, today announced that Dr. Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInvestorForum.com on June 24th. DATE: Thursday, June 24th TIME: 2:30 PM ETLINK: https
- GlobeNewswire
Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.comNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional i
- PR Newswire
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus.
